Berberine
Best for
Flatten post-meal blood sugar spikes
Likely strong benefit for 12–16 weeks · 6 meta-analyses , n=9.3k
40 papers · 8 claims · 64 outcomes scored · 8 positive
Outcomes
What berberine actually does, by outcome
Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.
Blunts the glucose surge after eating so energy stays level.
Shrinks fat deposits in the liver and calms the inflammation driving disease forward.
Keeps fasting glucose and your three-month average in a healthier range.
Your cells respond to insulin again so your pancreas works less hard.
Reduces the blood fats that rise after meals and drive heart risk.
Targets the visceral fat that wraps around your organs and drives inflammation.
Less weight on your joints, better blood markers, easier movement.
Your kidneys clear waste from the blood more effectively.
| Outcome | Effect | Evidence | Dose | Weeks | Rank |
|---|---|---|---|---|---|
| Flatten post-meal blood sugar spikes Likely strong benefit | | 12 meta-analyses n=9.3k Meta-analyzed | 0.09–9000 mg | 12–16 wk | #3/51 |
| Reverse fatty liver buildup Proven strong benefit | | 5 RCTs n=645 | 500–1500 mg | 12–26 wk | #1/17 |
| Steady your blood sugar levels Likely benefit | | 18 meta-analyses n=15k Meta-analyzed | 0.09–9000 mg | 6–54 wk | #3/109 |
| Improve insulin sensitivity Promising early signal | | 9 meta-analyses n=5.3k Meta-analyzed | 0.3–9000 mg | 8–54 wk | #4/78 |
| Lower triglycerides Likely modest benefit | | 18 meta-analyses n=12k Meta-analyzed | 0.3–9000 mg | 4–54 wk | #6/89 |
| Reduce belly and deep abdominal fat Faint early signal | | 7 meta-analyses n=1.9k Meta-analyzed | 0.3–1500 mg | 12–54 wk | — |
| Lose weight on the scale Likely real but unnoticeable | | 14 meta-analyses n=5.3k Meta-analyzed | 0.3–9000 mg | 6–54 wk | #5/75 |
| Improve kidney filtration rate Likely real but unnoticeable | | 1 meta-analysis n=582 Meta-analyzed | 300–9000 mg | — | #2/16 |
Recommended Berberine products
Real products that dose Berberine where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.
-
Nootropics Depot
Berberine HCL Capsules 380 mg
Well dosed 1,520 mg/day A formulaBrand audit 87/100
-
Allergy Research Group
Berberine 500
Well dosed 1,500 mg/day B formulaBrand audit 83/100
-
SuperSmart
Berberine 1000 mg
Well dosed 1,000 mg/day A formulaBrand audit 63/100
-
XYMOGEN
ALAmax Protect
Well dosed 1,000 mg/day A formulaBrand audit 80/100
-
Thorne
Berberine
Well dosed 900 mg/day A formulaBrand audit 79/100
-
Double Wood Supplements
Berberine 500 mg
Well dosed 2,000 mg/day B formulaBrand audit 75/100
Chosen for adequate Berberine dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.
Risk profile
Adverse events and known drug interactions
Safety events
Drug interactions
Co-studied with
Supplements that share evidence with berberine
- Drug:Amoxicillin 14 shared outcomes · d=0.14
-
Redyeastrice 13 shared outcomes · d=0.61 - Policosanol 9 shared outcomes · d=0.59
- Drug:Rabeprazole 7 shared outcomes · d=0.14
- Drug:Vonoprazan 7 shared outcomes
- Silymarin 4 shared outcomes · d=1.03
-
Chitosan 4 shared outcomes · d=0.65 -
Monacolin 4 shared outcomes · d=0.65 -
Hydroxytyrosol 4 shared outcomes · d=0.65 -
Bifidobacteriumadolescentis 4 shared outcomes · d=0.46 -
Probiotics 1 shared outcome · d=0.73
Sources
- 1. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. (2015) ↑
- 2. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. (2016) ↑
- 3. The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. (2020) ↑
- 4. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. (2021) ↑
- 5. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. (2022) ↑
- 6. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. (2022) ↑
- 7. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. (2024) ↑
- 8. Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research. (2025) ↑
- 9. The effects of berberine on depressive symptoms: a systematic review and meta-analysis of preclinical studies. (2025) ↑
- 10. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026) ↑
Generated August 14, 2026
Related
More evidence for Berberine
Evidence guide
Berberine
NewFrom Monk's Yellow to Metabolic Clues: What Berberine Really Does (and Doesn't) Do
Evidence guide
May 1, 2026
Ranking
Fatty Liver Disease
NewBest Supplements for Fatty Liver Disease (NAFLD), Ranked by Evidence
Evidence ranking
Apr 4, 2026
Systematic review
Systematic review
NewBerberine for Metabolic Health: A Systematic Evidence Review
GRADE evidence review
May 25, 2026
Evidence brief
Berberine · Lower total cholesterol
NewBerberine for Total Cholesterol: What 23 Trials Show
Focused evidence brief
May 11, 2026
Evidence map
Metabolic health
NewMetabolic health: evidence map across 82 supplements
Evidence coverage map
Jul 30, 2026
Ingredient evidence
Ingredient evidence
NewChitosan
All scored outcomes
Aug 14, 2026